A clinicopathologic staging system for diffuse malignant peritoneal mesothelioma (DMPM) stratifies survival through tumor-node-metastasis (TNM) criteria. Using prospectively collected data from 8 institutions, the developers identified 3 prognostic factors independently associated with survival: peritoneal cancer index, lymph node status, and extra-abdominal metastasis. The developers based the TNM system on these 3 factors, which they identified as influenced by disease progression from a set of 7 factors associated with improved survival in their univariate analysis of the data.
Breast cancer is the most common cancer among women. In 2010, there were an estimated 207,090 new cases and 39,840 deaths.1 Despite many improvements in the treatment of breast cancer, about 20% to 30% of women with the disease will progress to metastatic breast cancer (MBC). Although MBC remains incurable, a variety of treatment options are available. The US Food and Drug Administration (FDA) recently approved eribulin (Halaven), providing an exciting new option for women with heavily pretreated MBC.
Poly(ADP-ribose) polymerase (PARP) are a group of enzymes that are essential for base excision repair.1 There are several members of the PARP family, of which PARP1 is the most extensively studied.1,2 PARP1 only detects single-stranded DNA breaks and initiates repair; without PARP1, a single-stranded break is converted into a double-stranded break and repaired by homologous repair.1 PARP inhibition shows promise in BRCA1/2- deficient tumors, which lack homologous repair capability, causing synthetic lethality (decrease in repair of both single- and double-st Read More ›
ACOSOG Z1031: Neoadjuvant Comparison between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2/3 Breast Cancer Read More ›
Objective response rates, median progression-free survival, and overall survival increased in patients with metastatic renal cell carcinoma (RCC) and sunitinib-induced hypertension, according to results of a retrospective analysis of more than 500 RCC patients treated with sunitinib. The rate of adverse events did not increase in hypertensive patients, except for renal adverse events (5% vs 3%). Because of the ease of clinical monitoring, the researchers concluded that, if prospectively validated, sunitinib-induced hypertension will make a desirable biomarker in these patients.
Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
